GlassScriptPhysician profile
Karin Raaberg
NPI 1346839297
$13,990.09
in general payments reported to CMS, 2019-2025
20 companies · $4,565 in 2025
The $4,565 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $262 · 2022: $1,698 · 2023: $3,759 · 2024: $3,706 · 2025: $4,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,779.88 |
| Education | $249.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,577.67 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $1,915.09 | 2021-2025 | |
| Alkermes, INC. | $1,730.75 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,529.13 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,124.14 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $919.49 | 2021-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $623.80 | 2023-2025 | Sunosi, Auvelity |
| E.R. Squibb & Sons, L.L.C. | $473.48 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $444.87 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $377.42 | 2024-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $369.14 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $344.93 | 2022-2024 | Trintellix |
| Corium, LLC | $174.90 | 2022-2024 | Azstarys, Azstarys |
| Neurocrine Biosciences, INC. | $131.85 | 2024 | Ingrezza |
| Vertical Pharmaceuticals, LLC | $91.91 | 2024 | Relexxii |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $44.00 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $36.84 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $32.77 | 2025 | Mounjaro, Zepbound |
| Indivior INC. | $29.96 | 2022 | |
| Avion Pharmaceuticals | $17.95 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Raaberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.